

CITATION REPORT

List of articles citing

Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy

DOI: 10.1016/s0090-4295(96)00184-7
Urology, 1996, 48, 326-34.

Source: <https://exaly.com/paper-pdf/26698242/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
526	Characterization and glutamyl preferring carboxypeptidase function of prostate specific membrane antigen: a novel folate hydrolase. <i>Urology</i> , 1997 , 49, 104-12	1.6	109
525	Prognostic markers in localized prostate cancer: from microscopes to molecules. 1998 , 17, 429-37		9
524	Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. 1998 , 82, 2256-61		45 ¹
523	Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. 1998 , 83, 2259-2269		150
522	Prostate-specific membrane antigen. 1998 , 81, 523-8		5
521	ISOLATION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES SPECIFIC FOR THE EXTRACELLULAR DOMAIN OF PROSTATE SPECIFIC MEMBRANE ANTIGEN. 1998 , 160, 2396-2401		51
520	Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. <i>Urology</i> , 1998 , 52, 637-40	1.6	434
519	(111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY. 1998 , 159, 2041-2047		134
518	Capromab pendetide. A review of its use as an imaging agent in prostate cancer. 1998 , 12, 293-304		23
517	Prostate-specific membrane antigen (FOLH1): recent advances in characterising this putative prostate cancer gene. 1999 , 2, 180-185		4
516	Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. 1999 , 2, 264-276		209
515	Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. 1999 , 18, 483-90		45
514	Cloning and characterization of the prostate-specific membrane antigen promoter. 1999 , 74, 395-405		19
513	Activation of Rb and decline in androgen receptor protein precede retinoic acid-induced apoptosis in androgen-dependent LNCaP cells and their androgen-independent derivative. 1999 , 179, 336-46		62
512	Molecular expression of PSMA mRNA and protein in primary renal tumors. 1999 , 80, 799-803		32
511	Androgen receptor gene amplification increases tissue PSA protein expression in hormone-refractory prostate carcinoma. 1999 , 189, 219-23		30
510	Future prospects in prostate cancer. <i>Prostate</i> , 1999 , 40, 261-8	4.2	34

509	Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. <i>Prostate</i> , 1999 , 41, 127-33	4.2	207
508	Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. <i>Urology</i> , 1999 , 54, 1058-63	1.6	87
507	MOLECULAR DETERMINATION OF SURGICAL MARGINS USING FOSSA BIOPSIES AT RADICAL PROSTATECTOMY. 1999 , 161, 1442-1448		31
506	Short term neoadjuvant androgen deprivation therapy does not affect prostate specific membrane antigen expression in prostate tissues. 2000 , 88, 407-415		23
505	Prostate-specific membrane antigen (PSMA): current benefits and future value. 2000 , 18, 10-6		44
504	Detection of extraprostatic prostate cells utilizing reverse transcription-polymerase chain reaction. 2000 , 18, 17-28		28
503	Alterations of prostate biomarker expression and testosterone utilization in human LNCaP prostatic carcinoma cells by garlic-derived S-allylmercaptocysteine. <i>Prostate</i> , 2000 , 45, 304-14	4.2	45
502	Isolation and characterization of monoclonal antibodies specific for protein conformational epitopes present in prostate-specific membrane antigen (PSMA). 2000 , 19, 249-57		24
501	Generation of a baculovirus recombinant prostate-specific membrane antigen and its use in the development of a novel protein biochip quantitative immunoassay. 2000 , 19, 12-21		37
500	The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. 2000 , 5, 97-103		6
499	Prostate-specific membrane antigen: present and future applications. <i>Urology</i> , 2000 , 55, 622-9	1.6	31
498	PSP94 EXPRESSION AFTER ANDROGEN DEPRIVATION THERAPY: A COMPARATIVE STUDY WITH PROSTATE SPECIFIC ANTIGEN IN BENIGN PROSTATE AND PROSTATE CANCER. 2000 , 164, 1819-1824		32
497	PSMA specific antibodies and their diagnostic and therapeutic use. 2001 , 10, 511-9		46
496	Nutrition and Cancer Prevention. 2001 ,		3
495	A tissue-specific enhancer of the prostate-specific membrane antigen gene, FOLH1. 2001 , 73, 243-54		78
494	Metastatic renal cell carcinoma neovasculature expresses prostate-specific membrane antigen. <i>Urology</i> , 2001 , 57, 801-5	1.6	104
493	Comparison of anti-prostate-specific membrane antigen antibodies and other immunomarkers in metastatic prostate carcinoma. <i>Urology</i> , 2001 , 57, 1179-83	1.6	93
492	In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. <i>Urology</i> , 2001 , 58, 132-9	1.6	41

491	A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters. 2001 , 8, 927-35		22
490	3 Alterations of genes and their expression in prostate carcinoma. 2002 , 307-320		
489	Pharmacotherapy for biochemical recurrences after therapy for localised prostate cancer. 2002 , 3, 657-69		
488	In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. 2002 , 5, 36-46		72
487	Novel prostate-specific promoter derived from PSA and PSMA enhancers. 2002 , 6, 415-21		77
486	SELDI proteinchip MS: a platform for biomarker discovery and cancer diagnosis. 2002 , 2, 549-63		115
485	Prostate cancer gene therapy and the role of radiation. 2002 , 28, 49-64		7
484	The clinical role of prostate-specific membrane antigen (PSMA). 2002 , 7, 7-12		34
483	Upregulation of prostate specific membrane antigen/folate hydrolase transcription by an enhancer. 2002 , 285, 247-56		57
482	Induction of antibodies against prostate-specific membrane antigen (PSMA) by vaccination with a PSMA DNA vector. 2002 , 42, 67-73		4
481	Inhibition of prostate-specific membrane antigen (PSMA)-positive tumor growth by vaccination with either full-length or the C-terminal end of PSMA. 2002 , 102, 244-9		10
480	Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. 2002 , 83, 20-9		66
479	Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. <i>Prostate</i> , 2002 , 53, 9-23	4.2	73
478	Development of gene therapy using prostate-specific membrane antigen promoter/enhancer with Cre Recombinase/LoxP system for prostate cancer cells under androgen ablation condition. 2002 , 93, 1154-63		13
477	Recombinant glutamate carboxypeptidase II (prostate specific membrane antigen--PSMA)--cellular localization and bioactivity analyses. 2003 , 22, 317-26		5
476	Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. 2003 , 107, 323-9		67
475	Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. <i>Prostate</i> , 2003 , 54, 249-57	4.2	111
474	Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. <i>Prostate</i> , 2003 , 55, 9-19	4.2	20

473	Effect of carbohydrate moieties on the folate hydrolysis activity of the prostate specific membrane antigen. <i>Prostate</i> , 2003 , 57, 140-51	4.2	32
472	Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. 2003 , 10, 907-17		15
471	Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. 2003 , 170, 1717-21		200
470	NFATc1 with AP-3 site binding specificity mediates gene expression of prostate-specific-membrane-antigen. 2003 , 330, 749-60		27
469	Editorial comment. 2003 , 21, 353		
468	Prostate Cancer Methods and Protocols. 2003 ,		4
467	A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. 2003 , 14, 4835-45		150
466	Human prostate cancer cell lines. 2003 , 81, 21-39		47
465	Targeted alpha therapy of prostate cancer. 2003 , 81, 333-57		1
464	Targeted alpha-therapy for control of micrometastatic prostate cancer. 2004 , 4, 459-68		24
463	Targeting gene therapy for prostate cancer. 2004 , 10, 531-55		16
462	Targeting prostate-specific membrane antigen in cancer therapy: can molecular medicine be brought to the surface?. 2004 , 3, 559-60		6
461	Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. 2004 , 22, 2522-31		259
460	Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). 2004 , 3, 551-8		85
459	Targeting prostate cancer with conditionally replicative adenovirus using PSMA enhancer. 2004 , 10, 1051-8		18
458	Detection of prostate cancer and predicting progression: current and future diagnostic markers. 2004 , 10, 3943-53		134
457	Treatment efficiency of a suicide gene therapy using prostate-specific membrane antigen promoter/enhancer in a castrated mouse model of prostate cancer. 2004 , 95, 367-70		15
456	Molecular targeting of angiogenesis for imaging and therapy. 2004 , 31, 1327-41		29

455	Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. 2004 , 53, 411-21		63
454	Biodistributions of intact monoclonal antibodies and fragments of BLCA-38, a new prostate cancer directed antibody. 2004 , 53, 533-42		17
453	High-throughput chemiluminometric determination of prostate-specific membrane antigen mRNA in peripheral blood by RT-PCR using a synthetic RNA internal standard. 2004 , 380, 90-7		5
452	Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. 2004 , 6, 222-9		
451	Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. <i>Prostate</i> , 2004 , 58, 145-55	4.2	55
450	Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. <i>Prostate</i> , 2004 , 60, 141-52	4.2	45
449	Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. <i>Prostate</i> , 2004 , 61, 12-25	4.2	54
448	Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. <i>Prostate</i> , 2004 , 61, 1-11	4.2	52
447	Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. 2004 , 91, 528-39		552
446	Antigenic expression of human metastatic prostate cancer cell lines for in vitro multiple-targeted alpha-therapy with ²¹³ Bi-conjugates. 2004 , 60, 896-908		19
445	Co-administration of a DNA vaccine encoding the prostate specific membrane antigen and CpG oligodeoxynucleotides suppresses tumor growth. 2004 , 2, 29		9
444	Management of Prostate Cancer. 2004 ,		2
443	Gene-based therapy in prostate cancer. 2004 , 5, 469-79		21
442	Validation of molecular targets in prostate cancer. 2005 , 96 Suppl 2, 23-9		9
441	Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. 2005 , 116, 415-21		49
440	Targeting osseous metastases: rationale and development of radio-immunotherapy for prostate cancer. 2005 , 6, 163-70		
439	Antibody-based therapeutics: focus on prostate cancer. 2005 , 24, 521-37		36
438	Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. <i>Prostate</i> , 2005 , 62, 253-9	4.2	20

437	GENE THERAPY FOR PROSTATE CANCER. 2005 , 75-105		
436	Understanding Prostate-Specific Membrane Antigen and Its Implication in Prostate Cancer. 2005 , 597-615		1
435	Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. 2005 , 11, 7454-61		112
434	Is prostate-specific membrane antigen a multifunctional protein?. 2005 , 288, C975-81		144
433	Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. 2005 , 11, 7195s-7200s		100
432	Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. 2005 , 23, 4591-601		406
431	N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2005 , 4, 704-14	6.1	24
430	Construction of prostate-specific expressed recombinant plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. 2005 , 26, 215-21		13
429	Targeted therapies for prostate cancer. 2005 , 9, 283-98		10
428	Future therapies in hormone-refractory prostate cancer. <i>Urology</i> , 2005 , 65, 9-16; discussion 17	1.6	44
427	Expression of prostate specific membrane antigen in androgen-independent prostate cancer cell line PC-3. 2005 , 435, 1-14		51
426	Immunotherapy for Prostate Cancer. 2006 , 5, 331-339		
425	Treatment of Prostate Cancer in the 21st CenturyFuture Directions. 2006 , 5, 824-829		0
424	Future innovations in treating advanced prostate cancer. 2006 , 33, 247-72, viii		3
423	The evolution of imaging in advanced prostate cancer. 2006 , 33, 133-46, v		11
422	Immunotherapy for prostate cancer: what's the future?. 2006 , 20, 965-83, xi		5
421	Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature. 2006 , 72, 54-61		21
420	Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro. <i>Prostate</i> , 2006 , 66, 867-75	4.2	43

419	A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. <i>Prostate</i> , 2006 , 66, 1359-70	4.2	58
418	Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human. <i>Prostate</i> , 2006 , 66, 903-10	4.2	36
417	Two-step transcriptional amplification-lipid-based nanoparticles using PSMA or midkine promoter for suicide gene therapy in prostate cancer. 2006 , 97, 787-98		11
416	Successful in vivo tumor targeting of prostate-specific membrane antigen with a highly efficient J591/PEI/DNA molecular conjugate. 2006 , 13, 761-72		55
415	Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. 2006 , 4, 249-56		23
414	Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. 2006 , 1, 299-302		31
413	Technology insight: monoclonal antibody imaging of prostate cancer. 2006 , 3, 216-25		99
412	Analysis of prostate-specific membrane antigen splice variants in LNCap cells. 2006 , 16, 186-95		21
411	Targeting gene therapy for prostate cancer cells by liposomes complexed with anti-prostate-specific membrane antigen monoclonal antibody. 2006 , 17, 997-1005		27
410	Characterization of the androgen receptor in a benign prostate tissue-derived human prostate epithelial cell line: RC-165N/human telomerase reverse transcriptase. 2007 , 10, 30-8		16
409	Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles. 2007 , 15, 342-50		6
408	2-5A ligands--a new concept for the treatment of prostate cancer. 2007 , 26, 1471-7		6
407	Clinical trials of cancer therapies targeting prostate-specific membrane antigen. 2007 , 2, 182-90		61
406	Combined androgen blockade therapy can convert RT-PCR detection of prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) transcripts from positive to negative in the peripheral blood of patients with clinically localized prostate cancer and increase biochemical failure-free survival after curative therapy. 2007 , 45, 1488-94		18
405	Global expression analysis of prostate cancer-associated stroma and epithelia. 2007 , 16, 189-97		47
404	Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer. <i>Urology</i> , 2007 , 70, 303-8	1.6	8
403	Vaccine therapy for prostate cancer. 2007 , 25, 451-9		8
402	Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. 2007 , 38, 696-701		326

401	Preferential association of prostate cancer cells expressing prostate specific membrane antigen to bone marrow matrix. 2007 ,		1
400	Ligand-based vascular targeting of disease. 2007 , 2, 22-40		45
399	High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. <i>Prostate</i> , 2007 , 67, 1791-800	4.2	18
398	Molecular staging of prostate cancer in the year 2007. 2007 , 25, 19-30		35
397	1alpha,25-Dihydroxyvitamin D3 down-regulates expression of prostate specific membrane antigen in prostate cancer cells. <i>Prostate</i> , 2008 , 68, 773-83	4.2	11
396	Selective gene therapy for prostate cancer cells using liposomes conjugated with IgM type monoclonal antibody against prostate-specific membrane antigen. 2005 , 18, 17-23		9
395	Expression of prostate-specific membrane antigen in renal cortical tumors. 2008 , 21, 727-32		25
394	Improved effects of a double suicide gene system on prostate cancer cells by targeted regulation of prostate-specific membrane antigen promoter and enhancer. 2008 , 15, 442-8		6
393	Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. 2008 , 58, 687-94		28
392	Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. 2008 , 105, 17356-61		805
391	Novel tracers and their development for the imaging of metastatic prostate cancer. 2008 , 49, 2031-41		109
390	Prostate-specific membrane antigen associates with anaphase-promoting complex and induces chromosomal instability. <i>Molecular Cancer Therapeutics</i> , 2008 , 7, 2142-51	6.1	24
389	Moderate expression of prostate-specific membrane antigen, a tissue differentiation antigen and folate hydrolase, facilitates prostate carcinogenesis. 2008 , 68, 9070-7		46
388	Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). 2008 , 7, 974-82		60
387	Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. 2008 , 68, 7110-9		59
386	Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. 2008 , 26, 2147-54		120
385	Indium-111 capromab pendetide in the management of recurrent prostate cancer. 2008 , 8, 175-81		49
384	Glutamate Carboxypeptidase II. 2008 ,		0

383	Putative tissue markers in prostate cancer. 2008 , 75, 149-155		1
382	Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes. 2009 , 22, 1341-7		19
381	Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance. 2009 , 15, 101-14		77
380	Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. 2009 , 18, 1001-11		161
379	Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer. 2009 , 69, 6932-40		232
378	Biodistributions of ¹⁷⁷ Lu- and ¹¹¹ In-labeled 7E11 antibodies to prostate-specific membrane antigen in xenograft model of prostate cancer and potential use of ¹¹¹ In-7E11 as a pre-therapeutic agent for ¹⁷⁷ Lu-7E11 radioimmunotherapy. 2009 , 11, 159-66		24
377	Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. 2009 , 15, 167-72		222
376	The HLA-A2-restricted PSMA peptide LLHETDSAV is poorly immunogenic in patients with metastatic prostate cancer. <i>Prostate</i> , 2009 , 69, 142-8	4.2	7
375	Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. <i>Prostate</i> , 2009 , 69, 1101-8	4.2	111
374	Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. <i>Prostate</i> , 2009 , 69, 1579-85	4.2	76
373	Biorecognition and subcellular trafficking of HPMA copolymer-anti-PSMA antibody conjugates by prostate cancer cells. 2009 , 6, 959-70		53
372	Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. 2009 , 27, 26-32		11
371	Tissue-selective RNA interference in prostate cancer cell using prostate specific membrane antigen promoter/enhancer. 2009 , 27, 539-47		12
370	Design, synthesis, and preclinical evaluation of prostate-specific membrane antigen targeted (^{99m} Tc)-radioimaging agents. 2009 , 6, 790-800		129
369	Prostate cancer: role of SPECT and PET in imaging bone metastases. 2009 , 39, 396-407		90
368	Nanoparticles for Cancer Detection and Therapy. 2010 , 51		5
367	Vaccines as monotherapy and in combination therapy for prostate cancer. 2010 , 3, 116-22		9
366	Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. 2010 , 116, 1075-83		109

365	Promising tumor-associated antigens for future prostate cancer therapy. 2010 , 30, 67-101		23
364	Expression of prostate-specific membrane antigen (PSMA), increases cell folate uptake and proliferation and suggests a novel role for PSMA in the uptake of the non-polyglutamated folate, folic acid. <i>Prostate</i> , 2010 , 70, 305-16	4.2	98
363	Three conformational antibodies specific for different PSMA epitopes are promising diagnostic and therapeutic tools for prostate cancer. <i>Prostate</i> , 2010 , 70, 562-9	4.2	63
362	Prostate specific membrane antigen mRNA in blood as a potential predictor of biochemical recurrence after radical prostatectomy. 2010 , 25, 1291-5		7
361	Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. 2010 , 107, 17939-44		492
360	Drug Management of Prostate Cancer. 2010 ,		3
359	Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design. 2010 , 10, 19-28		26
358	Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies. 2010 , 29, 171		30
357	The choice of the antigen in the dendritic cell-based vaccine therapy for prostate cancer. 2010 , 36, 131-41		28
356	Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivo. 2011 , 108, 1850-5		417
355	In vitro and in vivo responses of advanced prostate tumors to PSMA ADC, an auristatin-conjugated antibody to prostate-specific membrane antigen. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1728-39	6.1	93
354	Targeting Strategies for Metal-Based Therapeutics. 2011 , 49-78		2
353	Baculoviruses as gene therapy vectors for human prostate cancer. 2011 , 107 Suppl, S59-70		14
352	Glutamate Carboxypeptidase II. 2011 ,		
351	. 2011 ,		115
350	Molecular Imaging and Metastasis. 516-537		
349	Role of TMPRSS2-ERG gene fusion in negative regulation of PSMA expression. 2011 , 6, e21319		18
348	Diagnostic performance of In-111 capromab pendetide SPECT/CT in localized and metastatic prostate cancer. 2011 , 36, 872-8		18

347	The role of single-photon emission computed tomography and SPECT/computed tomography in oncologic imaging. 2011 , 38, 87-108		22
346	The evolution of imaging in cancer: current state and future challenges. 2011 , 38, 3-15		57
345	Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. 2011 , 108, 9578-82		219
344	Prodrugs for improving tumor targetability and efficiency. 2011 , 63, 659-70		238
343	High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. <i>Prostate</i> , 2011 , 71, 281-8	4.2	179
342	DNA fusion gene vaccines induce cytotoxic T-cell attack on naturally processed peptides of human prostate-specific membrane antigen. 2011 , 41, 2447-56		14
341	2-(3-{1-Carboxy-5-[(6-[¹⁸ F]fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid, [¹⁸ F]DCFPyL, a PSMA-based PET imaging agent for prostate cancer. 2011 , 17, 7645-53		265
340	Targeting the internal epitope of prostate-specific membrane antigen with ⁸⁹ Zr-7E11 immuno-PET. 2011 , 52, 1608-15		53
339	Developing imaging strategies for castration resistant prostate cancer. 2011 , 50 Suppl 1, 39-48		44
338	Androgen-independent molecular imaging vectors to detect castration-resistant and metastatic prostate cancer. 2011 , 71, 6250-60		14
337	GAD1 is a biomarker for benign and malignant prostatic tissue. 2011 , 45, 39-45		13
336	¹²³ I-MIP-1072, a small-molecule inhibitor of prostate-specific membrane antigen, is effective at monitoring tumor response to taxane therapy. 2011 , 52, 1087-93		63
335	Prostate-specific membrane antigen-based therapeutics. 2012 , 2012, 973820		59
334	Advances in immuno-positron emission tomography: antibodies for molecular imaging in oncology. 2012 , 30, 3884-92		150
333	Molecular imaging of prostate cancer. 2012 , 22, 320-7		48
332	Biodistribution, tumor detection, and radiation dosimetry of ¹⁸ F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer. 2012 , 53, 1883-91		237
331	GCPII imaging and cancer. 2012 , 19, 1346-59		56
330	[Immunotherapy: an emerging strategies against prostate castration resistant cancer]. 2012 , 99 Suppl 1, S57-65		

329	Landmarks in prostate cancer diagnosis: the biomarkers. 2012 , 110 Suppl 1, 8-13	25
328	Measuring oncogenic signaling pathways in cancer with PET: an emerging paradigm from studies in castration-resistant prostate cancer. 2012 , 2, 985-94	15
327	DNA vaccination for prostate cancer, from preclinical to clinical trials - where we stand?. 2012 , 10, 9	11
326	Monoclonal antibody RM2 as a potential ligand for a new immunotracer for prostate cancer imaging. 2012 , 39, 944-7	1
325	Structure-activity relationships of 2P5Poligoadenylate analogue modifications of prostate-specific membrane antigen (PSMA) antagonists. 2012 , 31, 432-44	3
324	Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. 2012 , 7, e35976	161
323	Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. 2012 , 14, 401-7	37
322	Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates. 2012 , 12, 412-22	10
321	Nuclear Medicine Therapy. 2013 ,	3
320	Antibody-drug conjugate target selection: critical factors. 2013 , 1045, 29-40	41
319	Improved performance of SPECT-CT In-111 capromab pendetide by correlation with diffusion-weighted magnetic resonance imaging for identifying metastatic pelvic lymphadenopathy in prostate cancer. 2013 , 31, 1327-32	9
318	Prostate-specific membrane antigen protein expression in tumor tissue and risk of lethal prostate cancer. 2013 , 22, 2354-63	67
317	Opposing roles of folate in prostate cancer. <i>Urology</i> , 2013 , 82, 1197-203	1.6 23
316	Radioimmunotherapy of Prostate Carcinoma. 2013 , 265-277	
315	First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. 2013 , 54, 380-7	175
314	Anti-PSMA Antibody-Drug Conjugates and Immunotoxins. 2013 , 255-272	
313	Prostate Specific Membrane Antigen-Based Therapeutics. 2013 , 459-466	
312	Molecular Imaging in Diagnostics. 2013 , 193-205	

311	Prostate-specific membrane antigen-based imaging. 2013 , 31, 144-54		80
310	A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer. 2013 , 49, 2223-32		42
309	A multivalent approach of imaging probe design to overcome an endogenous anion binding competition for noninvasive assessment of prostate specific membrane antigen. 2013 , 10, 2975-85		8
308	Antibody-Drug Conjugates and Immunotoxins. 2013 ,		4
307	Prostate immunotherapy: should all guns be aimed at the prostate-specific antigen?. 2013 , 5, 907-10		4
306	Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. 2013 , 14, 14800-32		28
305	Next-generation therapy for residual prostate cancer. 2013 , 5, 1235-41		1
304	Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. 2013 , 3, 214		27
303	Prostate specific membrane antigen (PSMA): a novel modulator of p38 for proliferation, migration, and survival in prostate cancer cells. <i>Prostate</i> , 2013 , 73, 835-41	4.2	22
302	Targeted Radionuclide Therapy of Prostate Cancer. 2013 , 617-628		
301	Discriminatory Role of Detergent-Resistant Membranes in the Dimerization and Endocytosis of Prostate-Specific Membrane Antigen. 2013 , 8, e66193		7
300	Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. 2014 , 7, 2227-36		30
299	Antibody-drug conjugates targeting prostate-specific membrane antigen. 2014 , 19, 12-33		16
298	Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: A diagnostic pitfall. 2014 , 8, E941-3		1
297	. 2014 ,		
296	Words of wisdom. Re: Antibody-drug conjugates targeting prostate-specific membrane antigen. 2014 , 66, 1190-3		5
295	Ga-68-PSMA-PET/CT bei Prostatakarzinom. 2014 , 37, 38-44		
294	[Ga-68-PSMA PET/CT for prostate cancer]. 2014 , 45, 457-63		5

293	Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer. 2014 , 41, 89-101	32
292	Molecular imaging of urogenital diseases. 2014 , 44, 93-109	20
291	The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research. 2014 , 32, 272-9	115
290	Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer. 2014 , 134, 2284-93	96
289	Circulating tumour cells-monitoring treatment response in prostate cancer. 2014 , 11, 401-12	96
288	^{99m} Tc-labeled small-molecule inhibitors of prostate-specific membrane antigen: pharmacokinetics and biodistribution studies in healthy subjects and patients with metastatic prostate cancer. 2014 , 55, 1791-8	108
287	Targeted inhibition of prostate cancer metastases with an RNA aptamer to prostate-specific membrane antigen. 2014 , 22, 1910-22	83
286	Development of inhibitor-directed enzyme prodrug therapy (IDEPT) for prostate cancer. 2014 , 25, 1752-60	6
285	Management of Castration Resistant Prostate Cancer. 2014 ,	0
284	¹¹¹ In-labeled inhibitors of prostate-specific membrane antigen for PET imaging of prostate cancer. 2014 , 57, 2657-69	86
283	A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. 2014 , 191, 1439-45	62
282	Prostate cancer relevant antigens and enzymes for targeted drug delivery. 2014 , 187, 118-32	67
281	Role of immunotherapy in castration-resistant prostate cancer (CRPC). 2014 , 113, 367-75	3
280	Markers in Prostate Cancer. 2014 , 49-71	1
279	PSMA expression is highly homogenous in primary prostate cancer. 2015 , 23, 449-55	19
278	Evaluation of PSMA PET/CT imaging using a ⁶⁸ Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. 2015 , 36, 582-7	118
277	The clinical role of multimodality imaging in the detection of prostate cancer recurrence after radical prostatectomy and radiation therapy: past, present, and future. 2015 , 9, 570	5
276	PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status. 2015 , 5, 1388-401	151

275	(R)-NODAGA-PSMA: A Versatile Precursor for Radiometal Labeling and Nuclear Imaging of PSMA-Positive Tumors. 2015 , 10, e0145755	44
274	A Novel ^{111}In -Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer. 2015 , 56, 1094-9	78
273	Prostate cancer radiotherapy: potential applications of metal nanoparticles for imaging and therapy. 2015 , 88, 20150256	10
272	Prostate-specific membrane antigen-based imaging in prostate cancer: impact on clinical decision making process. <i>Prostate</i> , 2015 , 75, 748-57	4.2 53
271	Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. 2015 , 25, 1294-302	16
270	Evolving Strategies for Target Selection for Antibody-Drug Conjugates. 2015 , 32, 3494-507	61
269	Endosomal pH-Responsive Polymer-Based Dual-Ligand-Modified Micellar Nanoparticles for Tumor Targeted Delivery and Facilitated Intracellular Release of Paclitaxel. 2015 , 32, 2649-62	17
268	PSMA PET/CT with Glu-urea-Lys-(Ahx)- ^{111}Ta (HBED-CC) versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. 2015 , 42, 1794-800	93
267	PSMA PET in Prostate Cancer. 2015 , 56, 1131-2	40
266	In silico and biological analysis of anti-androgen activity of the brominated flame retardants ATE, BATE and DPTE in zebrafish. 2015 , 233, 35-45	7
265	Initial Evaluation of ^{18}F DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer. 2015 , 17, 565-74	304
264	PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. 2015 , 10, 375-86	69
263	^{111}Ta -DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. 2015 , 56, 1003-1010	155
262	Rezidivdiagnostik des Prostatakarzinoms mit PSMA-Liganden PET/CT und die initialen klinischen Erfahrungen mit der PSMA-basierten Radioligandentherapie. 2015 , 38, 124-130	2
261	Next revolution in molecular theranostics: personalized medicine for urologic cancers. 2015 , 11, 2205-19	10
260	Evaluation of Polymeric Nanomedicines Targeted to PSMA: Effect of Ligand on Targeting Efficiency. 2015 , 16, 3235-47	32
259	Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen. 2015 , 168, 105-10	8
258	Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. 2015 , 5, 66	89

257	Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. <i>Prostate</i> , 2015 , 75, 242-54	4.2	53
256	PSMA-mediated endosome escape-accelerating polymeric micelles for targeted therapy of prostate cancer and the real time tracing of their intracellular trafficking. 2015 , 7, 597-612		47
255	The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. 2015 , 42, 197-209		745
254	Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. 2016 , 6, 849-61		81
253	Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer. 2016 , 41, 478-80		17
252	Preliminary evaluation of prostate-targeted radiotherapy using (131) I-MIP-1095 in combination with radiosensitising chemotherapeutic drugs. 2016 , 68, 912-21		20
251	Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer. <i>Prostate</i> , 2016 , 76, 325-34	4.2	25
250	Prostate Specific Membrane Antigen Positron Emission Tomography May Improve the Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging in Localized Prostate Cancer. 2016 , 196, 1261-7		80
249	PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer. 2016 , 18, 411-9		146
248	Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer. 2016 , 196, 382-91		139
247	Prostate-specific membrane antigen-targeted liposomes specifically deliver the Zn(2+) chelator TPEN inducing oxidative stress in prostate cancer cells. 2016 , 11, 1207-22		26
246	Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology. 2016 , 24, 1267-77		71
245	Novel Therapies in Castration-Resistant Prostate Cancer. 2016 , 259-269		
244	PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. 2016 , 19, 223-30		99
243	PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer. 2016 , 144, 8-20		78
242	PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. 2016 , 57, 97S-104S		122
241	The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. 2016 , 57, 79S-89S		136
240	Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment. 2016 , 14, 1045-1053		21

239	Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer. 2016 , 46, 405-18		57
238	Prostate-Specific Membrane Antigen-Directed Therapy for Metastatic Castration-Resistant Prostate Cancer. 2016 , 22, 347-352		9
237	Theranostic Agents for Photodynamic Therapy of Prostate Cancer by Targeting Prostate-Specific Membrane Antigen. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1834-44	6.1	37
236	Nuclear Medicine Imaging of Prostate Cancer. 2016 , 188, 1037-1044		8
235	Characterization of a novel metastatic prostate cancer cell line of LNCaP origin. <i>Prostate</i> , 2016 , 76, 215-252		21
234	Correlation of Intraprostatic Tumor Extent with ^{67}Ga -PSMA Distribution in Patients with Prostate Cancer. 2016 , 57, 563-7		105
233	Preclinical and first clinical experience with the gastrin-releasing peptide receptor-antagonist [^{67}Ga]SB3 and PET/CT. 2016 , 43, 964-973		69
232	PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with ^{177}Lu -Labeled PSMA-617. 2016 , 57, 1170-6		354
231	Radioimmunotherapy for Prostate Cancer--Current Status and Future Possibilities. 2016 , 46, 165-79		18
230	New Clinical Indications for $^{18}\text{F}/^{11}\text{C}$ -choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. 2016 , 70, 161-175		154
229	Comparison of Prostate-Specific Membrane Antigen-Based ^{18}F -DCFBC PET/CT to Conventional Imaging Modalities for Detection of Hormone-Naïve and Castration-Resistant Metastatic Prostate Cancer. 2016 , 57, 46-53		99
228	Imaging of Prostate Cancer Using ^{64}Cu -Labeled Prostate-Specific Membrane Antigen Ligand. 2017 , 12, 193-203		9
227	Gallium-68 Prostate-Specific Membrane Antigen PET Imaging. 2017 , 12, 219-234		22
226	Detection Efficacy of Hybrid ^{67}Ga -PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. 2017 , 58, 1081-1087		50
225	Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with I-MIP-1095. 2017 , 44, 950-959		45
224	Tc-labeling and evaluation of a HYNIC modified small-molecular inhibitor of prostate-specific membrane antigen. 2017 , 48, 69-75		21
223	^{67}Ga or ^{18}F for Prostate Cancer Imaging?. 2017 , 58, 687-688		68
222	Diagnostic performance of ^{67}Ga -PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. 2017 , 44, 1258-1268		343

221	Comparison of PSMA-HBED and PSMA-I&T as diagnostic agents in prostate carcinoma. 2017 , 44, 1455-1462	26
220	Targeted Radionuclide Therapy: An Evolution Toward Precision Cancer Treatment. 2017 , 209, 277-288	46
219	Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis. 2017 , 20, 352-360	53
218	The role of PSMA PET/CT imaging in restaging of prostate cancer patients with low prostate-specific antigen levels. 2017 , 38, 149-155	29
217	Ga-PSMA-11 PET/CT in Newly Diagnosed Carcinoma of the Prostate: Correlation of Intraprostatic PSMA Uptake with Several Clinical Parameters. 2017 , 58, 1943-1948	61
216	Near-Infrared Photoimmunotherapy Targeting Prostate Cancer with Prostate-Specific Membrane Antigen (PSMA) Antibody. 2017 , 15, 1153-1162	53
215	Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer. 2017 , 66, 1345-1357	16
214	Quantitative F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring. 2017 , 7, 25	13
213	More Than [?] for Prostate Cancer?. 2017 , 58, 1709-1710	8
212	Prostate-Specific Membrane Antigen Ligands for Imaging and Therapy. 2017 , 58, 67S-76S	132
211	Glu-Ureido-Based Inhibitors of Prostate-Specific Membrane Antigen: Lessons Learned During the Development of a Novel Class of Low-Molecular-Weight Theranostic Radiotracers. 2017 , 58, 17S-26S	72
210	Theranostik. 2017 , 23, 597-608	
209	The Role of PET/MR Imaging in Precision Medicine. 2017 , 12, 489-501	5
208	PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice. 2017 , 114, 13655-13660	9
207	Radiochemistry and Preclinical PET Imaging of Ga-Desferrioxamine Radiotracers Targeting Prostate-Specific Membrane Antigen. 2017 , 16, 1536012117737010	15
206	PSMA Ligands for PET Imaging of Prostate Cancer. 2017 , 58, 1545-1552	120
205	Influence of Androgen Deprivation Therapy on the Uptake of PSMA-Targeted Agents: Emerging Opportunities and Challenges. <i>Nuclear Medicine and Molecular Imaging</i> , 2017 , 51, 202-211	1.9 28
204	⁶⁸ Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. 2017 , 58, 81-84	120

203	[PSMA-targeted radioligand therapy in prostate cancer]. 2017 , 56, 32-39		18
202	MR- und PET-Bildgebung der Prostata. 2017 ,		1
201	Preclinical Evaluation and First Patient Application of ^{99m} Tc-PSMA-I&S for SPECT Imaging and Radioguided Surgery in Prostate Cancer. 2017 , 58, 235-242		110
200	PSMA-Targeted Theranostic Nanocarrier for Prostate Cancer. 2017 , 7, 2477-2494		46
199	Metal-Based PSMA Radioligands. <i>Molecules</i> , 2017 , 22,	4.8	33
198	Comparison of Ga-HBED-CC PSMA-PET/CT and multiparametric MRI for gross tumour volume detection in patients with primary prostate cancer based on slice by slice comparison with histopathology. 2017 , 7, 228-237		99
197	Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy. 2017 , 12, 176		27
196	Ga PSMA-11 PET with CT urography protocol in the initial staging and biochemical relapse of prostate cancer. 2017 , 17, 31		14
195	Is PSMA PET-CT Better than Bone Scan? When and Why. 2017 , 08,		
194	Positron emission tomography (PET) in primary prostate cancer staging and risk assessment. 2017 , 6, 413-423		24
193	Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials. 2018 , 123, 7-20		61
192	Imaging prostate cancer (PCa) with [^{99m} Tc(CO)]finasteride dithiocarbamate. 2018 , 61, 550-556		4
191	Pharmacological upregulation of prostate-specific membrane antigen (PSMA) expression in prostate cancer cells. <i>Prostate</i> , 2018 , 78, 758-765	4.2	32
190	Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. 2018 , 73, 656-661		99
189	Molecular Imaging of Prostate Cancer: Radiopharmaceuticals for Positron Emission Tomography (PET) and Single-Photon Emission Computed Tomography (SPECT). 2018 , 475-501		2
188	Flare on Serial Prostate-Specific Membrane Antigen-Targeted ¹⁸ F-DCFPyL PET/CT Examinations in Castration-Resistant Prostate Cancer: First Observations. 2018 , 43, 213-216		9
187	Current status of theranostics in prostate cancer. 2018 , 45, 471-495		80
186	⁶⁸ Ga-PSMA-HBED-CC PET/CT imaging in Black versus White South African patients with prostate carcinoma presenting with a low volume, androgen-dependent biochemical recurrence: a prospective study. 2018 , 39, 179-185		9

185	The Utility of PET/CT in the Planning of External Radiation Therapy for Prostate Cancer. 2018 , 59, 557-567	31
184	Prostate cancer: updates on current strategies for screening, diagnosis and clinical implications of treatment modalities. 2018 , 39, 307-317	20
183	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. 2018 , 18, 354	10
182	Ga-PSMA-617 PET/CT: a promising new technique for predicting risk stratification and metastatic risk of prostate cancer patients. 2018 , 45, 1852-1861	29
181	Structure-activity relationships of succinimidyl-Cys-C(O)-Glu derivatives with different near-infrared fluorophores as optical imaging probes for prostate-specific membrane antigen. 2018 , 26, 2291-2301	4
180	F-PSMA-1007 PET/CT at 60 and 120 minutes in patients with prostate cancer: biodistribution, tumour detection and activity kinetics. 2018 , 45, 1329-1334	38
179	Receptor Occupancy Imaging Studies in Oncology Drug Development. 2018 , 20, 43	9
178	PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis. 2018 , 8, 4254	78
177	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 2018 , 73, 178-211	313
176	Clinical performance of Ga-PSMA-11 PET/MRI for the detection of recurrent prostate cancer following radical prostatectomy. 2018 , 45, 20-30	56
175	Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. 2018 , 59, 177-182	20
174	Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer. <i>Prostate</i> , 2018 , 78, 54-63	4.2 34
173	Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. 2018 , 59, 469-478	202
172	Repeated Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. 2018 , 59, 459-465	54
171	The feasibility of prostate-specific membrane antigen positron emission tomography(PSMA PET/CT)-guided radiotherapy in oligometastatic prostate cancer patients. 2018 , 20, 484-490	30
170	99mTc-PSMA Radioliganden für die SPECT Bildgebung von Prostatakrebs [Eine Alternative zu PET?]. 2018 , 41, 326-334	
169	Integration of PSMA-targeted PET imaging into the armamentarium for detecting clinically significant prostate cancer. 2018 , 28, 493-498	4
168	New Prostate Cancer Targets for Diagnosis, Imaging, and Therapy: Focus on Prostate-Specific Membrane Antigen. 2018 , 8, 653	39

167	Importance of Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist. 2018 , 37, 302-314	5
166	Diagnostic Accuracy of Ga-PSMA-11 PET/MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. 2018 , 289, 730-737	75
165	Ga-PSMA PET/CT in patients with recurrent prostate cancer after radical treatment: prospective results in 314 patients. 2018 , 45, 2035-2044	50
164	Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 2176-2186	61 22
163	PET/CT With Ga-PSMA in Prostate Cancer: Radiopharmaceutical Background and Clinical Implications. 2018 , 11, 4-13	21
162	PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives. 2018 , 13, 90	27
161	Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. 2018 , 45, 2045-2054	71
160	Radiotherapy for recurrent prostate cancer: 2018 Recommendations of the Australian and New Zealand Radiation Oncology Genito-Urinary group. 2018 , 129, 377-386	25
159	Diagnostic performance of F-PSMA-1007 PET/CT in patients with biochemical recurrent prostate cancer. 2018 , 45, 2055-2061	76
158	Importance of 68Ga-PSMA PET/CT in hospital practice. View of the radiation oncologist. 2018 , 37, 302-314	
157	Re: Isabel Rauscher, Charlotte Döwle, Bernhard Haller, et al. Efficacy, Predictive Factors, and Prediction Nomograms for Ga-labeled Prostate-specific Membrane Antigen-ligand Positron-emission Tomography/Computed Tomography in Early Biochemical Recurrent Prostate Cancer After Radical Prostatectomy. <i>Eur Urol</i> 2018;73:656-61. Clinical Significance of Prostate-specific Membrane Antigen Immunohistochemistry and Role of the Uropathologists. 2018 , 74, e141-e144	3
156	Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging. 2018 , 45, 503-524	19
155	Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. 2018 , 1, 78-82	40
154	The Use of MRI and PET Imaging Studies for Prostate Cancer Management: Brief Update, Clinical Recommendations, and Technological Limitations. 2019 , 7,	4
153	Hybrid Imaging for Male Malignancies. 2019 , 899-924	
152	New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2019 , 16, 523-538	5.5 13
151	Enhancing PSMA-uptake with androgen deprivation therapy - a new way to detect prostate cancer metastases?. 2019 , 45, 459-467	8
150	The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research. 2019 , 11,	31

149	68Ga-RM2 PET in PSMA- positive and -negative prostate cancer patients. 2019 , 58, 352-362		7
148	PSMA SPECT/CT with Tc-MIP-1404 in biochemical recurrence of prostate cancer: predictive factors and efficacy for the detection of PSMA-positive lesions at low and very-low PSA levels. 2019 , 33, 891-898		10
147	Historical review of pharmacological development and dosimetry of PSMA-based theranostics for prostate cancer. <i>Journal of Radioanalytical and Nuclear Chemistry</i> , 2019 , 322, 237-248	1.5	9
146	Phase 1 study of PSMA ADC, an antibody-drug conjugate targeting prostate-specific membrane antigen, in chemotherapy-refractory prostate cancer. <i>Prostate</i> , 2019 , 79, 604-613	4.2	27
145	Prostate cancer and inflammation: A new molecular imaging challenge in the era of personalized medicine. 2019 , 68-69, 66-79		11
144	Early lesion detection with F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer. 2019 , 46, 1911-1918		39
143	Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of Lu-PSMA-617 in LNCaP cells. <i>Prostate</i> , 2019 , 79, 1450-1456	4.2	3
142	The role of (Ga)PSMA I&T in biochemical recurrence after radical prostatectomy: detection rate and the correlation between the level of PSA, Gleason score, and the SUV. 2019 , 33, 545-553		6
141	Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (Lu-J591) for metastatic castration-resistant prostate cancer. 2019 , 125, 2561-2569		58
140	Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer. 2019 , 2, e1169		6
139	Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. 2019 , 16, 2590-2604		15
138	Development of Bispecific NT-PSMA Heterodimer for Prostate Cancer Imaging: A Potential Approach to Address Tumor Heterogeneity. 2019 , 30, 1314-1322		5
137	The proteasome inhibitor, bortezomib, induces prostate cancer cell death by suppressing the expression of prostate-specific membrane antigen, as well as androgen receptor. 2019 , 54, 1357-1366		2
136	Targeted Radionuclide Therapy: New Advances for Improvement of Patient Management and Response. <i>Cancers</i> , 2019 , 11,	6.6	20
135	Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy. 2019 , 37, 1535-1542		17
134	Radionuclide Therapy of Metastatic Prostate Cancer. 2019 , 49, 313-325		36
133	68Ga PSMA PET-CT: New Hope in Prostate Cancer Imaging and Therapy. 2019 , 22, 53-57		
132	Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. 2019 , 44, 365-376		11

131	[Ga]PSMA PET/CT Improves Initial Staging and Management Plan of Patients with High-Risk Prostate Cancer. 2019 , 21, 574-581		26
130	Outcome and safety of rechallenge [Lu]Lu-PSMA-617 in patients with metastatic prostate cancer. 2019 , 46, 1073-1080		34
129	Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. 2019 , 25, 903-917		4
128	Diagnostic Performance of Radiolabeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging in Newly Diagnosed Intermediate to High-Risk Prostate Cancer Patients: A Systematic Review and Meta-Analysis. 2019 , 102, 27-36		35
127	The value of tumor markers in men with metastatic prostate cancer undergoing [Lu]Lu-PSMA therapy. <i>Prostate</i> , 2020 , 80, 17-27	4.2	16
126	Ga-PSMA-11 PET/CT in patients with recurrent prostate cancer-a modified protocol compared with the common protocol. 2020 , 47, 624-631		16
125	Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients. 2020 , 47, 9-15		26
124	Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with Ga-PSMA-11 PET/MRI in men with treatment-naïve prostate cancer. 2020 , 47, 665-673		23
123	Image-Guided Surgery: Are We Getting the Most Out of Small-Molecule Prostate-Specific-Membrane-Antigen-Targeted Tracers?. 2020 , 31, 375-395		23
122	Modelling of the Lu/Lu radionuclide generator. 2020 , 166, 109261		0
121	Immunotherapy for Localized Prostate Cancer: The Next Frontier?. 2020 , 47, 443-456		5
120	PSMA-Directed CAR T Cells Combined with Low-Dose Docetaxel Treatment Induce Tumor Regression in a Prostate Cancer Xenograft Model. 2020 , 18, 226-235		8
119	Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. 2020 , 17, 3392-3402		5
118	Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy. 2020 , 13,		7
117	Does bone scintigraphy still have a role in the era of 68[Ga]PSMA PET/CT in prostate cancer?. 2020 , 34, 476-485		4
116	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. <i>Cancers</i> , 2020 , 12,	6.6	35
115	Prostate-specific membrane antigen (PSMA) expression in adenoid cystic carcinoma of the head and neck. 2020 , 20, 519		10
114	An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells. <i>Cancers</i> , 2020 , 12,	6.6	4

113	Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer. 2020 , 15, e0226219		9
112	Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?. 2020 , 38, 129-136		17
111	Commentary RE: Upregulation of PSMA Following Androgen Deprivation Therapy. <i>Urology</i> , 2020 , 145, 329-330	1.6	0
110	Regulation of CEACAM5 and Therapeutic Efficacy of an Anti-CEACAM5-SN38 Antibody-drug Conjugate in Neuroendocrine Prostate Cancer. 2021 , 27, 759-774		9
109	Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5
108	[F]-JK-PSMA-7 and [F]-FDG tumour PET uptake in treated xenograft human prostate cancer model in mice. 2021 , 48, 1773-1784		1
107	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. 2021 , 27, 2050-2060		2
106	Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. 2021 , 11, 630589		8
105	Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer. 2021 , 23, 59		1
104	Antihormone treatment differentially regulates PSA secretion, PSMA expression and Ga-PSMA uptake in LNCaP cells. 2021 , 147, 1733-1743		2
103	Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer. 2021 , 62, 596-604		16
102	PSMA-D4 Radioligand for Targeted Therapy of Prostate Cancer: Synthesis, Characteristics and Preliminary Assessment of Biological Properties. 2021 , 22,		4
101	Androgen deprivation therapy and its modulation of PSMA expression in prostate cancer: mini review and case series of patients studied with sequential [68Ga]-Ga-PSMA-11 PET/CT. 2021 , 9, 215-220		2
100	Standardization of the [Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer. 2021 , 14,		1
99	Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [F]DCFPyL PET Imaging. 2021 , 23, 745-755		2
98	Impact of short-term Dutasteride treatment on prostate-specific membrane antigen expression in a mouse xenograft model. 2021 , e1418		1
97	More Than Meets the Eye: Scientific Rationale behind Molecular Imaging and Therapeutic Targeting of Prostate-Specific Membrane Antigen (PSMA) in Metastatic Prostate Cancer and Beyond. <i>Cancers</i> , 2021 , 13,	6.6	2
96	Darolutamide Potentiates the Antitumor Efficacy of a PSMA-targeted Thorium-227 Conjugate by a Dual Mode of Action in Prostate Cancer Models. 2021 , 27, 4367-4378		2

95	Prostate-specific Membrane Antigen Biology in Lethal Prostate Cancer and its Therapeutic Implications. 2021 ,		3
94	The Diagnostic Role of F-Choline, F-Fluciclovine and F-PSMA PET/CT in the Detection of Prostate Cancer With Biochemical Recurrence: A Meta-Analysis. 2021 , 11, 684629		12
93	Photodynamic Therapy: Targeting Cancer Biomarkers for the Treatment of Cancers. <i>Cancers</i> , 2021 , 13,	6.6	12
92	PET/CT Imaging of Prostate Cancer. Modern Versions of Radiopharmaceuticals. 2021 , 4, 23-36		
91	Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management. <i>Cancers</i> , 2021 , 13,	6.6	3
90	Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitors. 2021 , 11, 14925		2
89	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. 2021 ,		3
88	Antibodies targeting Prostate-Specific Membrane Antigen positive prostate cancer: from diagnostic imaging to theranostics. 2021 , 33, 500-506		0
87	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. 2021 , 22,		4
86	Diagnostic potential of serum extracellular vesicles expressing prostate-specific membrane antigen in urologic malignancies. 2021 , 11, 15000		0
85	Prospective assessment of AR splice variant and PSMA detection on circulating tumor cells of mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial (NCT04188275). 2021 , 38, 451-458		1
84	Radionuclide Therapy in Prostate Cancer: from standalone to combination PSMA theranostics. 2021 ,		4
83	Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer. 2021 , 30, 63-66		1
82	A PSMA-targeted bispecific antibody for prostate cancer driven by a small-molecule targeting ligand. 2021 , 7,		4
81	Prostate-Specific Membrane Antigen (PSMA) PET: A Counterpart to Prostate MRI. 2021 , 56, 376-383		
80	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with Ac-PSMA-617 targeted alpha-radiation therapy. 2021 , 39, 729.e7-729.e16		14
79	The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. 2021 , 27, 2928-2937		17
78	Antiproliferative effects of garlic-derived and other allium related compounds. 2001 , 492, 83-106		17

77	Biology of PSMA As a Diagnostic and Therapeutic Target. 2004 , 609-630	1
76	Immunological Complexity of the Prostate Cancer Microenvironment Influences the Response to Immunotherapy. 2019 , 1210, 121-147	7
75	Nanobodies Targeting Prostate-Specific Membrane Antigen for the Imaging and Therapy of Prostate Cancer. 2020 , 63, 7601-7615	7
74	Chapter 3:Glutamate Carboxypeptidase II as a Therapeutic Target. 2011 , 62-95	2
73	Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen?. 1999 , 9, 391-5	7
72	Myc confers androgen-independent prostate cancer cell growth. 2003 , 112, 1724-31	86
71	Myc confers androgen-independent prostate cancer cell growth. 2003 , 112, 1724-1731	153
70	Uptake of F-DCFPyL in Paget's Disease of Bone, an Important Potential Pitfall in Clinical Interpretation of PSMA PET Studies. 2015 , 1, 81-84	25
69	Pitfalls in Gallium-68 PSMA PET/CT Interpretation-A Pictorial Review. 2018 , 4, 182-193	52
68	Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging. 2017 , 8, 10919-10930	14
67	68Ga-PSMA-11 PET/CT for prostate cancer staging and risk stratification in Chinese patients. 2017 , 8, 12247-12258	17
66	PSMA-homing dsRNA chimeric protein vector kills prostate cancer cells and activates anti-tumor bystander responses. 2017 , 8, 24046-24062	5
65	In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer. 2016 , 7, 22531-42	15
64	Genitourinary Tumors: Update on Molecular Biomarkers for Diagnosis, Prognosis and Prediction of Response to Therapy. 2019 , 20, 305-312	7
63	PET imaging in prostate cancer: focus on prostate-specific membrane antigen. 2013 , 13, 951-62	150
62	Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer. 2019 , 63, 7-18	15
61	Assessment of biochemical recurrence of prostate cancer (Review). 2019 , 55, 1194-1212	8
60	Clinical Utility of Gallium-68 PSMA PET/CT Scan for Prostate Cancer. 2017 , 32, 110-117	20

- 59 Radioiodine therapy for castration-resistant prostate cancer following prostate-specific membrane antigen promoter-mediated transfer of the human sodium iodide symporter. **2014**, 16, 120-3 7
- 58 Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?. **2018**, 33, 202-208 4
- 57 Role of Early Dynamic Positron Emission Tomography/Computed Tomography with ⁶⁸Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results. **2018**, 33, 112-117 4
- 56 Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer. **2020**, 12, e7147 5
- 55 Novel Redirected T-Cell Immunotherapies for Advanced Prostate Cancer. **2021**, 2
- 54 Monoclonal Antibodies for Imaging and Therapy of Prostate Cancer. **2000**, 305-315
- 53 Monoclonal Antibodies in the Management of Prostate Cancer. **2004**, 135-147
- 52 Novel Biomarkers for Disease Diagnosis, Prognosis, and Prediction. **2006**, 39-57
- 51 Molecular Imaging, Clinical Trial Design, and the Development of Emerging Therapies for Metastatic Prostate Cancer. **2006**, 291-313
- 50 Cancer Immunology, Immunotherapeutics, and Vaccine Approaches. **2010**, 305-319
- 49 Design, development, and translation of poxvirus-based vaccines for cancer. **2011**, 56-77 1
- 48 Prostate Cancer: Role of Conventional Radionuclide and Hybrid Bone Imaging. **2012**, 635-659
- 47 Tumor Markers. **2013**, 423-444
- 46 New Imaging Modalities. **2014**, 43-63
- 45 Prostate Cancer. **1999**, 83-102
- 44 Physikalisch-technische Grundlagen und Tracerentwicklung in der Positronenemissionstomografie. **2017**, 19-56
- 43 PSMA-Based Therapy of Metastasized Castrate-Resistant Prostate Cancer. **2018**, 451-464
- 42 ^{99m}Tc-PSMA Radionuclide imaging of prostate cancer: an innovative diagnostic direction in nuclear medicine. **2020**, 26-38

41	Initial Experience of Clinical Use of [Tc]Tc-PSMA-T4 in Patients with Prostate Cancer. A Pilot Study. 2021 , 14,		1
40	Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer?. 2021 , 62, 650-657		1
39	Antimetastatic Gene Therapy. 2005 , 299-319		
38	Gene Therapy for Advanced Prostate Cancer. 2007 , 139-163		
37	PSA-targeted Alpha-, Beta- and Positron Emitting Immuno-Theranostics in Murine Prostate Cancer Models and Non-Human Primates.		
36	Overview of prostate-specific membrane antigen. 2004 , 6 Suppl 10, S13-8		104
35	The emergence of radioimmunosintigraphy for prostate cancer. 2006 , 8 Suppl 1, S20-8		3
34	⁶⁸ Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?. 2017 , 70, 37-43		5
33	Combining radionuclide therapy with radiotherapy. 2021 ,		
32	Delivery of antisense oligonucleotides for splice-correction of androgen receptor pre-mRNA in castration-resistant prostate cancer models using cell-penetrating peptides.. <i>Prostate</i> , 2022 ,	4.2	2
31	Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells.. 2022 , 23,		0
30	A low molecular weight multifunctional theranostic molecule for the treatment of prostate cancer.. 2022 , 12, 2335-2350		0
29	PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial.. <i>Nature Medicine</i> , 2022 ,	50.5	12
28	Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC.. <i>Cancers</i> , 2022 , 14,	6.6	1
27	Impact of Three-Month Androgen Deprivation Therapy on [⁶⁸ Ga]Ga-PSMA-11 PET/CT Indices in Men with Advanced Prostate Cancer-Results from a Pilot Prospective Study.. <i>Cancers</i> , 2022 , 14,	6.6	1
26	Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.. <i>Molecules</i> , 2021 , 26,	4.8	0
25	The safety and efficacy of CAR-T cells in the treatment of prostate cancer: Review. <i>Biomarkers</i> , 2021 , 1-52	2.6	
24	Nano-Theranostics for the Sensing, Imaging and Therapy of Prostate Cancers.. <i>Frontiers in Chemistry</i> , 2022 , 10, 830133	5	0

23	Preclinical development of a novel [68Ga]Ga-/[177Lu]Lu-labeled agent for PSMA-targeted imaging and therapy. <i>Journal of Radioanalytical and Nuclear Chemistry</i> ,	1.5	0
22	Imaging of tumor-associated vascular prostate specific membrane antigen in woodchuck model of hepatocellular carcinoma. 2022 ,		
21	Androgen receptor genomic alterations and treatment resistance in metastatic prostate cancer. <i>Prostate</i> , 2022 , 82,	4.2	1
20	PSMA theragnostics for metastatic castration resistant prostate cancer. <i>Translational Oncology</i> , 2022 , 22, 101438	4.9	1
19	Biological impediments to monoclonal antibodyBased cancer immunotherapy. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1493-1501	6.1	40
18	Interval Changes in PSMA PET/CT During Radium-223 Therapy for Metastatic Bone Disease from Castration-Resistant Prostate Cancer. <i>Nuclear Medicine and Molecular Imaging</i> , 2022 , 56, 188-195	1.9	
17	The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer. <i>Nature Reviews Urology</i> ,	5.5	0
16	Disulfide-constrained peptides that bind to the extracellular portion of the prostate-specific membrane antigen. 2004 , 3, 597-603		16
15	Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells. 13,		0
14	Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization.		0
13	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. 2022 , 10, 1872		2
12	Clinical Applications of PSMA PET Examination in Patients with Prostate Cancer. 2022 , 14, 3768		1
11	Modular Smart Molecules for PSMA-Targeted Chemotherapy.		
10	References. 2023 , 113-141		0
9	PSA-Stratified Performance of [18F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy. 2022 , 12, 2212		1
8	Prostate-Specific Membrane Antigen-Based PET Brings New Insights into the Management of Prostate Cancer. 2022 ,		0
7	Using PSMA imaging for prognostication in localized and advanced prostate cancer.		0
6	Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET. 2022 , 14, 6194		0

- 5 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer. **2023**, 100583 ○
- 4 PSMA Receptor-Based PET-CT: The Basics and Current Status in Clinical and Research Applications. **2023**, 13, 158 1
- 3 Theranostics in Prostate Cancer. **2023**, 655-704 ○
- 2 Molecular Imaging in Oncology. **2023**, 303-373 ○
- 1 Phase 1 Study of Safety and Preliminary Clinical Activity of JNJ-63898081, a PSMA and CD3 Bispecific Antibody, for Metastatic Castration-Resistant Prostate Cancer. **2023**, ○